By Paul A. Harris
Portland, Ore., June 27 - Valeant Pharmaceuticals International, Inc. priced $3,225,000,000 of senior notes (B1/B) in two tranches on Thursday, according to market sources.
The deal included a $1.6 billion tranche of five-year notes that priced at par to yield 6¾%. The yield printed on top of yield talk.
In addition, the company priced a $1,625,000,000 tranche of eight-year notes at par to yield 7½%.
The yield printed on top of yield talk. The initial guidance was in the mid-6% range.
A proposed tranche of 10-year notes was withdrawn.
Goldman Sachs & Co. was the left bookrunner for the Rule 144A for life deal. BofA Merrill Lynch, Barclays, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and RBC Capital Markets are the joint bookrunners.
The issuing entity will be VPII Escrow Corp., a newly formed, wholly owned Canadian subsidiary of Valeant Pharmaceuticals International.
Proceeds will be used to help finance the acquisition of Bausch + Lomb.
Valeant is a Laval, Quebec-based specialty pharmaceutical company. Bausch + Lomb is a Rochester, N.Y.-based eye health company.
Issuer: | VPII Escrow Corp.
|
Amount: | $3,225,000,000
|
Securities: | Senior notes
|
Left bookrunner: | Goldman Sachs & Co.
|
Joint bookrunners: | BofA Merrill Lynch, Barclays, J.P. Morgan Securities, LLC, Morgan Stanley & Co. LLC, RBC Capital Markets
|
Co-managers: | DNB Markets, SunTrust Robinson Humphrey, HSBC, Mitsubishi UFJ, TD Securities
|
Trade date: | June 27
|
Settlement date: | July 12
|
Ratings: | Moody's: B1
|
| Standard & Poor's: B
|
Distribution: | Rule 144A and Regulation S for life
|
Marketing: | Roadshow
|
|
Five-year notes
|
Amount: | $1.6 billion
|
Maturity: | Aug. 15, 2018
|
Coupon: | 6¾%
|
Price: | Par
|
Yield: | 6¾%
|
Spread: | 529 bps
|
Call protection: | Two years
|
Price talk: | 6¾% area
|
|
Eight-year notes
|
Amount: | $1,625,000,000
|
Maturity: | July 15, 2021
|
Coupon: | 7½%
|
Price: | Par
|
Yield: | 7½%
|
Spread: | 531 bps
|
Call protection: | Three years
|
Price talk: | 7½% area
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.